Current information urges a shift in the
strategy for assessment of Cd risks in the general
population, moving away from a unique
focus on renal tubular proteinuria. Bone
effects will likely contribute more than kidney
effects to the overall risk. Bone effects, along
with other non-renal effects such as cancer,
should also be considered in the health risk
assessment of Cd.